Novanta Acquires Riverpoint Medical for $1.45 Billion

Novanta Inc. has agreed to acquire Riverpoint Medical, a specialist in minimally invasive surgical consumables, for a substantial enterprise value of $1.45 billion. The transaction, announced by seller Arlington Capital Partners, includes an upfront cash payment of $1.2 billion, with an additional $250 million contingent on achieving specific milestones in early 2027. This acquisition marks a significant exit for Arlington, highlighting Riverpoint's evolution into a key player in advanced medical device manufacturing.

Riverpoint Medical has carved out a niche by designing and producing proprietary, private-label products for leading original equipment manufacturers (OEMs) in the medical technology sector. The company's expertise lies in high-growth areas such as fiber-based, polymer, and bioabsorbable devices, crucial for life-saving procedures. Its differentiated offerings are underpinned by proprietary material science and coating technologies, including advanced bio-integrative implant designs and osteoconductive coatings. A key competitive advantage is Riverpoint's capability to manage the entire 510(k) clearance process for its clients, streamlining market entry for complex medical devices.

The strategic expansion of Riverpoint's operational footprint has been a critical factor in its growth trajectory. The company operates an 81,000-square-foot manufacturing and design facility in Portland, Oregon, its original base. Complementing this is a recently established campus in Costa Rica, a strategically positioned nearshore hub that facilitates close proximity to major OEM customer facilities. This dual-location strategy enhances manufacturing flexibility and supply chain efficiency, catering to the demands of the global medical device market, which is projected to reach over $600 billion by 2027, with minimally invasive surgical devices representing a significant growth segment.

Arlington Capital Partners, a private investment firm focused on regulated industries, partnered with Riverpoint in 2019. During their stewardship, Arlington facilitated a significant transformation, nearly quadrupling the company's revenue primarily through organic expansion. This growth was driven by strengthening the leadership team, enhancing commercial operations, scaling manufacturing capabilities in both the U.S. and Costa Rica, and broadening market reach. "When we first partnered with Riverpoint, we recognized a company with exceptional engineering talent and differentiated capabilities in surgical fiber and biomedical textiles," stated Matt Altman, a Managing Partner at Arlington. "Together with the management team, we’ve meaningfully expanded its product portfolio, scaled its manufacturing, and broadened its end markets."

The acquisition by Novanta is seen as a logical next step for Riverpoint, providing the resources and scale to further accelerate innovation and market penetration. Doug J. King, CEO of Riverpoint, expressed confidence in the transition: "Arlington was the partner of choice to usher Riverpoint through this stage of growth because of their decades of success investing in and scaling medical manufacturing companies. Our collective success is the direct result of bringing together Riverpoint’s strong management team with Arlington’s deep sector and operational expertise." Novanta, a global manufacturer of advanced technology solutions, is expected to leverage Riverpoint's specialized capabilities to enhance its own offerings in the medical sector.

Gordon Auduong, a Managing Director at Arlington, emphasized Riverpoint's alignment with Arlington's investment thesis: "Riverpoint exemplifies the kind of businesses we set out to build at Arlington — mission-critical products, deep technical capability, and a culture of innovation. We’re proud of what this team has accomplished and are excited to see Riverpoint join Novanta, a strategic partner with the scale and resources to take its technologies to the next level." Arlington Capital Partners has a robust history of building leading companies within healthcare, aerospace, defense, and government services, with a portfolio that includes firms like Afton Scientific, AVS Bio, and Grand River Aseptic Manufacturing.